PMID- 26360500
OWN - NLM
STAT- MEDLINE
DCOM- 20160505
LR  - 20181202
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 14
IP  - 10
DP  - 2015 Oct
TI  - Safety and tolerability of antidepressant co-treatment in acute major depressive 
      disorder: results from a systematic review and exploratory meta-analysis.
PG  - 1587-608
LID - 10.1517/14740338.2015.1085970 [doi]
AB  - INTRODUCTION: Although antidepressant (AD) monotherapy is recommended first-line 
      for major depressive disorder (MDD), AD + AD co-treatment is common. AREAS 
      COVERED: We conducted the first systematic review searching 
      PubMed/MEDLINE/PsycInfo/Embase from database inception until 1 June 2015 for 
      acute randomized trials in >/= 20 adults with MDD comparing AD monotherapy with AD 
      + AD co-treatment that reported quantitative data on adverse events (AEs). 
      Meta-analyzing 23 studies (n = 2435, duration = 6.6 weeks) AD monotherapy and AD 
      + AD co-treatment were similar regarding intolerability-related discontinuation 
      (risk ratio [RR] = 1.38, 95% CI = 0.89 - 1.10) and frequency of >/= 1 AE (RR = 
      1.19, 95% CI = 0.95 - 1.49). Nevertheless, AD + AD co-treatment was associated 
      with significantly greater burden regarding 4/25 AEs (tremor: RR = 1.55, 95% CI = 
      1.01 - 2.38; sweating: RR = 1.95, 95% CI = 1.13 -3.38, >/= 7% weight gain: RR = 
      3.15, 95% CI = 1.34 - 7.41; weight gain = 2.17, 95% CI = 0.71 - 3.63 kg), but not 
      more CNS, gastrointestinal, sexual or alertness-related AEs. However, 11/25 AEs 
      (44.0%) were reported in only 1 - 2 studies. Adding noradrenergic and specific 
      serotonergic antidepressants (NaSSA) or tricyclic antidepressants (TCA) to 
      selective serotonin reuptake inhibitors (SSRIs) was specifically associated with 
      more AEs. EXPERT OPINION: The potential for increased AEs with AD + AD 
      co-treatment needs to be considered vis-a-vis unclear efficacy benefits of this 
      strategy. In particular, NaSSAs and TCAs should be added to SSRIs with caution. 
      Clearly, more data on side-effect burden of AD + AD co-treatment are needed.
FAU - Galling, Britta
AU  - Galling B
AD  - a 1 The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island 
      Jewish Health System , Glen Oaks, NY, USA +1 71 84 70 48 12 ; +1 71 83 43 16 59 ; 
      ccorrell@lij.edu.
FAU - Calsina Ferrer, Amat
AU  - Calsina Ferrer A
AD  - b 2 Institut d'Assistencia Sanitaria, Hospital de Santa Caterina , Salt, Spain.
FAU - Abi Zeid Daou, Margarita
AU  - Abi Zeid Daou M
AD  - c 3 Vanderbilt Psychiatric Hospital , Nashville, TN, USA.
FAU - Sangroula, Dinesh
AU  - Sangroula D
AD  - a 1 The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island 
      Jewish Health System , Glen Oaks, NY, USA +1 71 84 70 48 12 ; +1 71 83 43 16 59 ; 
      ccorrell@lij.edu.
FAU - Hagi, Katsuhiko
AU  - Hagi K
AD  - a 1 The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island 
      Jewish Health System , Glen Oaks, NY, USA +1 71 84 70 48 12 ; +1 71 83 43 16 59 ; 
      ccorrell@lij.edu.
AD  - d 4 Dainippon Sumitomo Pharma Co, Ltd , Osaka, Japan.
FAU - Correll, Christoph U
AU  - Correll CU
AD  - a 1 The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island 
      Jewish Health System , Glen Oaks, NY, USA +1 71 84 70 48 12 ; +1 71 83 43 16 59 ; 
      ccorrell@lij.edu.
AD  - e 5 Hofstra North Shore LIJ School of Medicine , Hempstead, NY, USA.
AD  - f 6 The Feinstein Institute for Medical Research , Manhasset, NY, USA.
AD  - g 7 Albert Einstein College of Medicine , Bronx, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20150910
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Antidepressive Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Depressive Disorder, Major/*drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
OTO - NOTNLM
OT  - adverse effects
OT  - antidepressant
OT  - augmentation
OT  - co-treatment
OT  - combination
OT  - depression
OT  - major depressive disorder
OT  - meta-analysis
OT  - safety
OT  - tolerability
EDAT- 2015/09/12 06:00
MHDA- 2016/05/06 06:00
CRDT- 2015/09/12 06:00
PHST- 2015/09/12 06:00 [entrez]
PHST- 2015/09/12 06:00 [pubmed]
PHST- 2016/05/06 06:00 [medline]
AID - 10.1517/14740338.2015.1085970 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2015 Oct;14(10):1587-608. doi: 
      10.1517/14740338.2015.1085970. Epub 2015 Sep 10.